Ask AI
Immunotherapy in Solid Tumor

CE / CME

Improving Outcomes With Immune Checkpoint Inhibitors for Solid Tumors

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: June 18, 2026

Expiration: December 17, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Patrick Forde, MD, PhD, reviews immune checkpoint inhibitor (IC) strategy, patient counseling, special populations, and toxicity management across solid tumors, with case-based discussion in metastatic non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC).

The activity focuses on selecting immunotherapy strategies using clinical context and guidelines, recognizing and managing immune-related adverse events (AEs), understanding recent data on subcutaneous (SC) formulations and perioperative immunotherapy, and supporting patient engagement throughout treatment.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Please note that Decera Clinical Education plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your individual responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with lung, colorectal, or skin cancer do you provide care for in a typical month?

Which best describes your practice setting?

Carmen is a 59-year-old former smoker with PD-L1–positive metastatic nonsquamous NSCLC. Her tumor has no actionable genomic alterations. Her Eastern Cooperative Oncology Group (ECOG) performance status (PS) is 1. She also has hypertension, mild controlled heart disease, and diabetes managed with semaglutide.

Which of the following would be least helpful when explaining to Carmen how her first-line immunotherapy strategy should be selected?